drugset
drugset / Trial / NCT04128423

Study of AMV564 in Subjects With Advanced Solid Tumors

NCT04128423 ↗

Phase 1 Unknown 65 enrolled Amphivena Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This Phase 1 study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AMV564 alone and in combination with Pembrolizumab in patients with advanced solid tumors.

Timeline

Start
2019-10-09
Primary completion
2021-12-15
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AMV564 Protein / enzyme biologic — —

Indications

No indication recorded.